Results 171 to 180 of about 5,523,377 (316)
Objective There are no US Food and Drug Administration–approved therapies for Raynaud phenomenon (RP) in the United States. Clinical trials have been challenged by study design. Important advances in RP patient‐reported outcome measures and mechanistic quantification allow RP‐related pain characterization.
Tracy M. Frech +4 more
wiley +1 more source
From safety commitment to safety behavior: The mediating role of safety awareness. [PDF]
Lu S, Zhu W, Zhang L, Ahmad H.
europepmc +1 more source
Objective We aimed to test the efficacy of personalized treatment of older Veterans with chronic low back pain (CLBP) delivered by Aging Back Clinics (ABC) as compared with usual care (UC). Methods Two hundred ninety‐nine Veterans age 65‐89 with CLBP from 3 VA medical centers underwent baseline testing, randomization to ABC or UC and 12 months follow ...
Debra K. Weiner +9 more
wiley +1 more source
Efficacy and safety of recombinant human activated protein C for severe sepsis.
G. R. Bernard +10 more
semanticscholar +1 more source
Safety Review for Clinical Application of Repetitive Transcranial Magnetic Stimulation
Won‐Seok Kim, Nam‐Jong Paik
openalex +1 more source
Objective Axial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti‐inflammatory treatment. Digital health applications (DHAs) provide innovative approaches to address multidimensional aspects of persistent pain through psychological and behavioral strategies. The aim of this study was to assess the impact of a DHA
David Kiefer +7 more
wiley +1 more source
Factors Associated With Patient Safety Activities of Clinical Nurses: A Cross-Sectional Secondary Data Analysis. [PDF]
Lee J, Nam KH, Suh Y, Lee Y, Lee D.
europepmc +1 more source
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
G. Demetri +20 more
semanticscholar +1 more source

